Embecta

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.

Earnings

News

Guidance

Health Care

Movers

Trading Ideas

General

EMBC

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business

Becton, Dickinson and Company (BDX)

Large Cap

Hedge Funds

Media

Activist investor Starboard Value is urging Becton Dickinson to sell its life sciences division, citing potential value gains. Analysts estimate a spin-off could boost the company&#39;s worth by up to 30%.

Activist Starboard Value Pushes Becton Dickinson To Divest Life Sciences Unit

movers image

Pre-Market Outlook

Markets

AEHR

ARDT

BLCO

CGBS

Aehr Test Systems Posts Weak Results, Joins Trump Media &amp; Technology Group And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Embecta Corp

Press Releases

embecta Celebrates National Diabetes Awareness Month by Ringing Nasdaq Closing Bell

embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results

UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results

Dividends

embecta Announces Quarterly Cash Dividend

Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs

embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

embecta to Report Fiscal First Quarter 2025 Financial Results

Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results

embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference

Align Tech

Avanos Medical

Bioventus

Cerus

The Cooper Companies, Inc. - Common Stock

Cooper Companies

Establishment Labs Holdings Inc. - Common Shares

Establishment Labs Hldgs

Haemonetics

ICU Medical

OrthoPediatrics

Lantheus Holdings

Merit Medical Systems, Inc. - Common Stock

Merit Medical Systems

Neogen

InspireMD

OraSure Technologies, Inc. - Common Stock

OraSure Technologies

Rockwell Medical

RxSight

Sanara MedTech

Solventum

Staar Surgical

TELA Bio

UFP Techs

Utah Medical Products, Inc. - Common Stock

Utah Medical Products

VolitionRX

Dentsply Sirona

Xtant Medical Holdings, Inc. Common Stock

Xtant Medical Hldgs

BTIG

Morgan Stanley

B of A Securities

Comments

Embecta

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga